Managing IBD Therapies in Pregnancy

Area of Science:

• Gastroenterology
• Obstetrics
• Pharmacology

Background:

• Inflammatory bowel disease (IBD) often affects women during childbearing years.
• Maintaining disease remission is vital for successful pregnancy outcomes.
• Many women with IBD require ongoing treatment during pregnancy.

Purpose of the Study:

• To review the current evidence on the safety of IBD medications during pregnancy and lactation.
• To inform healthcare providers for better patient counseling regarding medication adherence.
• To address concerns about potential adverse effects on fetal development.

Main Methods:

• Review of existing scientific literature and clinical studies on IBD medication safety in pregnancy.
• Analysis of data regarding various drug classes, including aminosalicylates, antibiotics, steroids, immunomodulators, anti-TNF agents, and anti-integrins.
• Synthesis of information on risks and benefits for both mother and fetus.

Main Results:

• Aminosalicylates, antibiotics, and steroids are generally considered low-risk.
• Immunomodulators and anti-TNF agents appear safe for use during pregnancy and breastfeeding.
• Combination therapy with biologics and immunomodulators may elevate infection risk; anti-integrins show potential safety but require more data.

Conclusions:

• Consistent IBD treatment is essential for achieving and maintaining remission during pregnancy.
• Most commonly used IBD medications have favorable safety profiles in pregnancy and lactation.
• Open communication between patients and providers is key for informed decision-making about IBD management during conception and pregnancy.